SEC Form 4 · accession 0001209191-19-006627
Sarepta Therapeutics, Inc. · SRPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sandesh Mahatme
Officer — EVP, CFO & CBO
Period of report
Jan 30, 2019
Accepted (ET)
Feb 1, 2019 · 8:24 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000873303
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 30, 2019 | M | 5,469 | $13.71 | A | 14,118 | D | |
| Common Stock | Jan 30, 2019 | M | 1,128 | $13.71 | A | 15,246 | D | |
| Common Stock | Jan 30, 2019 | M | 17,860 | $13.90 | A | 33,106 | D | |
| Common Stock | Jan 30, 2019 | M | 19,345 | $23.85 | A | 52,451 | D | |
| Common Stock | Jan 30, 2019 | S | 43,802 | $130.00 | D | 8,649 | D | |
| Common Stock | Jan 31, 2019 | M | 21,198 | $23.85 | A | 29,847 | D | |
| Common Stock | Jan 31, 2019 | S | 21,198 | $130.72 | D | 8,649 | D | |
| Common Stock | holding | — | — | — | 12,012 | I | By trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | $13.71 | Jan 30, 2019 | M | 5,469 | D | Feb 28, 2017 | Feb 28, 2026 | Common Stock | 5,469 | 7,404 | D |
| Stock Option (right to buy) | $13.71 | Jan 30, 2019 | M | 1,128 | D | Feb 28, 2017 | Feb 28, 2026 | Common Stock | 1,128 | 6,771 | D |
| Stock Option (right to buy) | $13.90 | Jan 30, 2019 | M | 17,860 | D | Feb 27, 2016 | Feb 27, 2025 | Common Stock | 17,860 | 0 | D |
| Stock Option (right to buy) | $23.85 | Jan 30, 2019 | M | 19,345 | D | Nov 5, 2013 | Nov 5, 2022 | Common Stock | 19,345 | 96,664 | D |
| Stock Option (right to buy) | $23.85 | Jan 31, 2019 | M | 21,198 | D | Nov 5, 2013 | Nov 5, 2022 | Common Stock | 21,198 | 75,466 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.